These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Severe homocysteinemia in two givosiran-treated porphyria patients: is free heme deficiency the culprit? Petrides PE; Klein M; Schuhmann E; Torkler H; Molitor B; Loehr C; Obermeier Z; Beykirch MK Ann Hematol; 2021 Jul; 100(7):1685-1693. PubMed ID: 34050373 [TBL] [Abstract][Full Text] [Related]
10. Leading RNA Interference Therapeutics Part 2: Silencing Delta-Aminolevulinic Acid Synthase 1, with a Focus on Givosiran. de Paula Brandão PR; Titze-de-Almeida SS; Titze-de-Almeida R Mol Diagn Ther; 2020 Feb; 24(1):61-68. PubMed ID: 31792921 [TBL] [Abstract][Full Text] [Related]
11. Recovery of chronic motor neuropathy due to acute intermittent porphyria after givosiran treatment in a young boy: a case report. Mazzoli M; Ricci A; Vaudano AE; Marcacci M; Marchini S; Bergonzini P; Di Pierro E; Pischik E; Iughetti L; Pietrangelo A; Meletti S; Ventura P Eur Rev Med Pharmacol Sci; 2024 Apr; 28(8):3268-3274. PubMed ID: 38708485 [TBL] [Abstract][Full Text] [Related]
12. Givosiran - Running RNA Interference to Fight Porphyria Attacks. Gonzalez-Aseguinolaza G N Engl J Med; 2020 Jun; 382(24):2366-2367. PubMed ID: 32521139 [No Abstract] [Full Text] [Related]
13. Case report of a complicated neurologically manifesting acute porphyria treated successfully with Givosiran. Steinberg T; Kilic M; Fuchs K; Hanyk K; Linker RA; Schlachetzki F; Neumann B J Neurol Sci; 2021 Mar; 422():117334. PubMed ID: 33581419 [No Abstract] [Full Text] [Related]